Active Hexose Correlated Compound (AHCC) Alleviates Gemcitabine-Induced Hematological Toxicity in Non-Tumor-Bearing Mice


Active hexose correlated compound (AHCC) is known as a dietary supplement derived from an extract of a basidiomycete mushroom. The present study was conducted to evaluate the role of AHCC in alleviating the side effects, particularly hematological toxicity, in non-tumor-bearing mice receiving monotherapy with gemcitabine (GEM). The results from the GEM treatment groups with and without AHCC administration were compared to control group that received vehicle alone. The GEM alone treatment reduced peripheral leukocytes and hemoglobin, and bone marrow cell viability in spite of no influence on body weight, food consumption, and renal and hepatic parameters. Supplementation with AHCC significantly alleviated these side effects. The colony forming assay of bone marrow cells revealed that AHCC improved reduction of colony forming unit-granulocyte macrophage (CFU-GM) and burst forming unit-erythroid (BFU-E) related to GEM administration. However, when mRNA expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin (EPO) was examined using a quantitative reverse transcription polymerase chain reaction (RT-PCR), AHCC showed no effect for the mRNA levels of their hematopoietic growth factors. These results support the concept that AHCC can be beneficial for cancer patients with GEM treatment through alleviating the hematotoxicity.

Share and Cite:

D. Nakamoto, K. Shigama, H. Nishioka and H. Fujii, "Active Hexose Correlated Compound (AHCC) Alleviates Gemcitabine-Induced Hematological Toxicity in Non-Tumor-Bearing Mice," International Journal of Clinical Medicine, Vol. 3 No. 5, 2012, pp. 361-367. doi: 10.4236/ijcm.2012.35069.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] L. Hertel, J. S. Kroin, J. W. Misner and J. M. Tustin, "Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2-difluoro-D-ribofuranosyl nucleotides," The Journal of Organic Chemistry, Vol. 53, 1988, pp. 2406-2409.
[2] V. Gandhi, S. Mineishi, P. Huang, Y. Yang, S. Chubb, A. J. Chapman, B. J. Nowak, L. W. Hertel and W. Plunkett, "Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells," Seminars in Oncology, Vol. 22, No. 4, 1995, pp. 61-67.
[3] V. Heinemann, Y. Z. Xu, S. Chubb, A. Sen, L. W. Hertel, G. B. Grindey and W. Plunkett, "Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2’,2’-difluorodeoxycytidine," Molecular Pharmacology, Vol. 38, No. 4, 1990, pp. 567-572.
[4] P. Huang, S. Chubb, L. W. Hertel, G. B. Grindey and W. Plunkett "Action of 2’,2’-difluorodeoxycytidine on DNA synthesis," Cancer Research, Vol. 51, No. 22, 1991, pp. 6110-6117.
[5] C. J. Campen, T. Dragovich and A. F. Baker, "Management strategies in pancreatic cancer," American Journal of Health-System Pharmacy, Vol. 68, No. 7, 2011, pp. 573-584.
[6] G. Bepler, K. E. Sommers, A. Cantor, X. Li, A. Sharma, C. Williams, A. Chiappori, E. Haura, S. Antonia, T. Tanvetyanon, G. Simon, C. Obasaju and L. A. Robinson, "Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer," Journal of Thoracic Oncology, Vol. 3, No. 10, 2008, pp. 1112-1118.
[7] D. L. Richardson, F. J. Backes, L. G. Seamon, V. Zanagnolo, D. M. O'Malley, D. E. Cohn, J. M. Fowler and L. J. Copeland, "Combination of gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer," Gynecologic Oncology, Vol. 111, No. 3, 2008, pp. 461-466.
[8] S. Moulder, N. Valkov, A. Neuger, J. Choi, J. H. Lee, S. Minton, P. Munster, J. Gump, M. Lacevic, R. Lush and D. Sullivan, "Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response," Cancer, Vol. 113, No. 10, 2008, pp. 2646-2654.
[9] J. W. Valle, H. Wasan, P. Johnson, E. Jones, L. Dixon, R. Swindell, S. Baka, A. Maraveyas, P. Corrie, S. Falk, S. Gollins, F. Lofts, L. Evans, T. Meyer, A. Anthoney, T. Iveson, M. Highley, R. Osborne and J. Bridgewater, "Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomized phase II study - The UK ABC-01 Study," British Journal of Cancer, Vol. 101, No. 4, 2009, pp. 621-627.
[10] M. Tonato, A. M. Mosconi and C. Martin, "Safety profile of gemcitabine," Anti-Cancer Drugs, Vol. 6, 1995, pp. 27-32.
[11] P. J. Mansky and D. B. Wallerstedt, "Complementary medicine in palliative care and cancer symptom management," The Cancer Journal, Vol. 12, No. 5, 2006, pp. 425-431.
[12] I. Hyodo, N. Amano, K. Eguchi, M. Narabayashi, J. Imanishi, M. Hirai, T. Nakano and S. Takashima, "Nationwide survey on complementary and alternative medicine in cancer patients in Japan," Journal of Clinical Oncology, Vol. 23, No. 12, 2005, pp. 2645-2654.
[13] N. Terakawa, Y. Matsui, S. Satoi, H. Yanagimoto, K. Takahashi, T. Yamamoto, J. Yamano, S. Takai, A. H. Kwon and Y. Kamiyama, "Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: a double-blind, placebo-controlled trial," Nutrition and Cancer, Vol. 60, No. 5, 2008, pp. 643-651.
[14] Y. Gao, D. Zhang, B. Sun, H. Fujii, K. Kosuna and Z. Yin, "Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses," Cancer Immunology, Immunotherapy, Vol. 55, No. 10, 2005, pp. 1258-1266.
[15] K. Matsushita, Y. Kuramitsu, Y. Ohiro, M. Obata, M. Kobayashi, Y. Q. Li and M. Hosokawa, "Combination therapy of active hexose correlated compound plus UFT significantly reduces the metastasis of rat mammary adenocarcinoma," Anti-Cancer Drugs, Vol. 9, No. 4, 1998, pp. 343-350.
[16] A. Hirose, E. Sato, H. Fujii, B. Sun, H. Nishioka and O. I. Aruoma, "The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice," Toxicology and Applied Pharmacology, Vol. 222, No. 2, 2007, pp. 152-158.
[17] Y. Matsui, J. Uhara, S. Satoi, M. Kaibori, H. Yamada, H. Kitade, A. Imamura, S. Takai, Y. Kawaguchi, A. H. Kwon and Y. Kamiyama, "Improved prognosis of postoperative hapatocellular carcinoma patients when treated with functional food: a prospective cohort study," Journal of Hepatology, Vol. 37, No. 1, 2002, pp. 78-86.
[18] S. Cowawintaweewat, S. Manoromana, H. Sriplung, T. Khuhaprema, P. Tongtawe, P. Tapchaisri and W. Chaicumpa, "Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment," Asian Pacific Journal of Allergy and Immunology, Vol. 24, No. 1, 2006, pp. 33-45.
[19] K. Shigama, A. Nakaya, K. Wakame, H. Nishioka and H. Fujii, "Alleviating effect of active hexose correlated compound (AHCC) for anticancer drug-induced side effects in non-tumor-bearing mice," Journal of Experimental Therapeutics and Oncology, Vol. 8, No. 1, 2009, pp. 43-51.
[20] B. Sun, K. Wakame, E. Sato, H. Nishioka, O. I. Aruoma and H. Fujii, "The effect of active hexose correlated compound in modulating cytosine arabinoside-induced hair loss, and 6-mercaptopurine- and methotrexate-induced liver injury in rodents," Cancer Epidemiology, Vol. 33, No. 3-4, 2009, pp. 293-299.
[21] M. Masse, C. Naegelen, N. Pellegrini, J. M. Segier, N. Marpaux and F. Beaujean, "Validation of a simple method to count vary low white cell concentrations in filtered red cells or platelets," Transfusion, Vol. 32, No. 6, 1992, pp. 565-571.
[22] L. Toschi, G. Finocchiaro, S. Bartolini, V. Gioia and F. Cappuzzo, "Role of gemcitabine in cancer therapy," Future Oncology, Vol. 1, No. 1, 2005, pp. 7-17.
[23] G. Maschmeyer and A. Haas, "The epidemiology and treatment of infections in cancer patients," International Journal of Antimicrobial Agents, Vol. 31, No. 3, 2008, pp. 193-197.
[24] D. C. Dale, "Colony-stimulating factors for the management of neutropenia in cancer patients," Drugs, Vol. 62, 2002, pp. 1-15.
[25] D. Cella, D. Dobrez and J. Glaspy, "Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes," Annals of Oncology, Vol. 14, 2003, pp. 511-519.
[26] T. Matsumoto, K. Endoh, K. Kamisango, K. Akamatsu, K. Koizumi, M. Higuchi, N. Imai, H. Mitsui and T. Kawaguchi, "Effect of recombinant human erythropoietin on anticancer drug-induced anaemia," British Journal of Haematology, Vol. 75, No. 4, 1990, pp. 463-468.
[27] D. Cella, M. J. Zagari, C. Vandorons, D. D. Gagnon, H. J. Hurtz and J. W. Nortier, "Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population," Journal of Clinical Oncology, Vol. 21, No. 2, 2003, pp. 366-373.
[28] M. Merlano, M. Benasso, G. M. Numico, M. Danova, A. Santelli, F. Ameli, F. Blengo, I. Ricci and M. Rosso, "5-Fluorouracil dose intensification and granulocyte-macrophage colony-stimulating factor in cisplatin-based chemotherapy for relapsed squamous cell carcinoma of the head and neck: a phase II study," American Journal of Clinical Oncology, Vol. 21, No. 3, 1998, pp. 313-316.
[29] E. Azoulay, H. Attalah, A. Harf, B. Schlemmer and C. Delclaux, "Granulocyte colony-stimulating factor or neu-trophil-induced pulmonary toxicity: myth or reality?" Chest, Vo. 120, No. 5, 2001, pp. 1695-1701.
[30] A. C. Hirbe, O. Uluckan, E. A. Morgan, M. C. Eagleton, J. L. Prior, D. Piwnica-Worms, K. Trinkaus, A. Apicelli, K. Weilbaecher, "Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner," Blood, Vol. 109, No. 8, 2007, pp. 3424-3431.
[31] P. Fu, X. Jiang and M. O. Arcasoy, "Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway," Biochemical and Bio-physical Research Communications, Vol. 379, No. 3, 2009, pp. 696-701.
[32] A. Mirmohammadsadegh, A. Marini, A. Gustrau, D. Delia, S. Nambiar, M. Hassan and U. R. Hengge, "Role of erythropoietin receptor expression in malignant melanoma," Journal of Investigative Dermatology, Vol. 130, No. 1, 2010, pp. 201-210.
[33] H. Lin, Y. H. She, B. R. Cassileth, F. Sirotnak and S. Cunningham-Rundles, "Maitake beta-glucan MD-fraction enhances bone marrow colony formation and reduces doxorubicin toxicity in vitro," International Immuno-pharmacology, Vol. 4, No. 1, 2004, pp. 91-99.
[34] H. Lin, S. W. Cheung, M. Nesin, B. R. Cassileth, S. Cunningham-Rundles, "Enhancement of umbilical cord blood cell hematopoiesis by Maitake beta-glucan is mediated granulocyte colony-stimulating factor production," Clinical and Vaccine Immunology, Vol. 14, No. 1, 2007, pp. 21-27.
[35] E. Suzuki, J. Sun, V. Kapoor, A. S. Jassar and S. M. Albelda, "Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects," Cancer Biology and Therapy, Vol. 6, No. 6, 2007, pp. 880-885.
[36] I. Matsuzaki, H. Suzuki, M. Kitamura, Y. Minamiya, H. Kawai and J. Ogawa, "Cisplatin induces fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells," Oncology, Vol. 59, No. 4, 2000, pp. 336-343.
[37] E. L. Spierings, H. Fujii, B. Sun and T. Walshe, "A phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers," Journal of Nutritional Science and Vitaminology, Vol. 53, 2007, pp. 536-539.
[38] C. M. Mach, H. Fujii, K. Wakame and J. Smith, "Evaluation of active hexose correlated compound hepatic metabolism and potential for drug interactions with chemotherapy agents," Journal of the Society for Integrative Oncology, Vol. 6, No. 3, 2008, pp. 105-109.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.